Tesamorelin – Stabilised GHRH Analogue for Research

Tesamorelin is an advanced synthetic analogue of human growth hormone-releasing hormone, also known as GHRH or growth hormone-releasing factor. It contains the complete 44-amino-acid sequence of human GRF with a specialised N-terminal trans-3-hexenoyl modification. This molecular modification supports improved resistance to rapid enzymatic degradation and gives Tesamorelin a more stable research profile than naturally occurring GHRH. Its clearly defined structure makes Tesamorelin particularly relevant for professional laboratory studies involving GHRH receptor activity, pituitary signalling, endogenous growth hormone release, the GH–IGF-1 axis and stabilised peptide development. Tesamorelin is supplied as a premium lyophilised research material in a securely sealed vial with clear batch information, professional packaging and fast order processing from Peptides Divas.

Key Product Features

• Synthetic human GHRH analogue
• Complete 44-amino-acid peptide sequence
• Also known by the research designation TH9507
• Specialised N-terminal hexenoyl modification
• Designed for improved molecular stability
• Relevant for GHRH receptor research
• Suitable for pituitary signalling studies
• Useful for GH and IGF-1 pathway research
• Supplied as a lyophilised research material
• Clear batch-specific product information
• Secure and discreet packaging
• Fast and trackable European delivery

What Is Tesamorelin?

Tesamorelin is a synthetic peptide based on the complete amino-acid sequence of naturally occurring human growth hormone-releasing hormone. Natural GHRH is produced in the hypothalamus and communicates with specialised receptors located on somatotroph cells within the anterior pituitary. This signalling system is involved in regulating the synthesis and pulsatile release of endogenous growth hormone. Naturally occurring GHRH is rapidly broken down by enzymes. Tesamorelin contains an N-terminal trans-3-hexenoyl group attached to its tyrosine residue, creating a stabilised GHRH analogue suitable for extended peptide and receptor research.

Molecular Structure

Tesamorelin contains 44 amino acids and retains the complete sequence of human GRF. Its structural characteristics include:

• Complete human GRF 1–44 sequence
• N-terminal tyrosine residue
• Trans-3-hexenoyl molecular modification
• C6 carbon chain containing a double bond
• Stabilised synthetic peptide structure
• GHRH receptor agonist activity
• Approximate molecular weight of 5.1 kDa
• Commonly prepared and analysed as an acetate salt

The hexenoyl modification differentiates Tesamorelin from unmodified human GHRH and shorter GHRH fragments.

GHRH Receptor Research

Tesamorelin is primarily studied in relation to the growth hormone-releasing hormone receptor. The GHRH receptor is a G-protein-coupled receptor expressed mainly on pituitary somatotroph cells. Activation of this receptor initiates intracellular signalling associated with growth hormone synthesis and secretion. Potential areas of laboratory research include:

• GHRH receptor binding
• Receptor activation
• Ligand–receptor interactions
• Cyclic AMP signalling
• Intracellular calcium pathways
• Pituitary somatotroph activity
• Receptor internalisation
• Receptor sensitivity
• Concentration-response relationships
• Comparative GHRH analogue pharmacology

The exact experimental conditions and analytical methods should be established by the qualified laboratory conducting the research.

Pituitary Signalling Research

The anterior pituitary is an important endocrine signalling centre responsible for releasing several protein and peptide hormones. Tesamorelin may be relevant for controlled laboratory studies involving:

• Somatotroph-cell signalling
• Endogenous growth hormone release
• Pulsatile hormone secretion
• Pituitary receptor expression
• Intracellular signal transduction
• Hormone-release kinetics
• Hypothalamic–pituitary communication
• Endocrine feedback mechanisms
• Comparative pituitary-cell assays
• GHRH-mediated cellular responses

Tesamorelin stimulates the GHRH pathway rather than acting as recombinant growth hormone itself.

GH–IGF-1 Axis Research

The growth hormone and insulin-like growth factor 1 axis forms an interconnected endocrine signalling network. GHRH receptor activation in the pituitary can influence endogenous growth hormone secretion. Growth hormone subsequently participates in signalling associated with IGF-1 production and broader endocrine feedback systems. Tesamorelin may therefore be studied in relation to:

• Growth hormone pulsatility
• GH secretion patterns
• IGF-1-associated signalling
• Endocrine feedback loops
• Hypothalamic–pituitary communication
• Hormone biomarker analysis
• Metabolic signalling pathways
• Protein-turnover mechanisms
• Comparative endocrine models
• Time-dependent hormone responses

These pathways describe areas of scientific interest and should not be interpreted as guaranteed effects from a non-pharmaceutical research material.

Stabilised Peptide Research

The N-terminal hexenoyl modification makes Tesamorelin particularly relevant for research into peptide stabilisation and molecular engineering. Potential research topics include:

• Resistance to enzymatic degradation
• N-terminal peptide modification
• Molecular half-life extension
• Peptide clearance
• Structure–activity relationships
• Long-acting peptide design
• Peptide pharmacokinetics
• Modified GHRH analogues
• Molecular stability
• Peptide formulation development

Researchers may compare Tesamorelin with native GHRH, sermorelin, Modified GRF 1–29 or other GHRH-related compounds.

Tesamorelin Versus Sermorelin

Tesamorelin and sermorelin are both related to human GHRH, but they are not identical compounds.

Characteristic	Tesamorelin
Peptide sequence	Human GRF 1–44
Peptide length	44 amino acids
Molecular modification	N-terminal trans-3-hexenoyl group
Primary receptor	GHRH receptor
Research profile	Stabilised full-length GHRH analogue
Alternative designation	TH9507

Sermorelin generally refers to the shorter GHRH 1–29 sequence and does not contain the same hexenoyl modification.

Tesamorelin Versus CJC-1295

Tesamorelin and CJC-1295 are both synthetic GHRH-related peptides, but their structures and stabilisation strategies differ. Tesamorelin contains the full 44-amino-acid human GRF sequence with an N-terminal hexenoyl modification. CJC-1295 with DAC uses a different modified peptide sequence and an albumin-binding Drug Affinity Complex. Researchers should not treat these compounds as interchangeable and should verify the exact product identity through batch-specific analytical documentation.

Metabolic Pathway Research

The GH–IGF-1 axis interacts with multiple metabolic and endocrine systems. Tesamorelin may be relevant for laboratory models involving:

• Lipid-related signalling
• Glucose-homeostasis pathways
• Protein metabolism
• Hepatic signalling
• Adipocyte biology
• Endocrine–metabolic communication
• Cellular energy regulation
• Hormone-responsive gene expression
• Metabolic biomarker analysis
• Comparative peptide research

Research results can vary according to the biological model, concentration, exposure duration and analytical method.

Potential Research Applications

Tesamorelin may be suitable for controlled scientific research involving:

• GHRH receptor pharmacology
• Pituitary somatotroph signalling
• Endogenous growth hormone secretion
• Growth hormone pulsatility
• GH–IGF-1 axis research
• Hypothalamic–pituitary communication
• Endocrine feedback mechanisms
• Peptide stabilisation
• N-terminal molecular modification
• Structure–activity relationships
• Metabolic signalling
• Analytical peptide characterisation
• Chromatographic analysis
• Mass-spectrometry analysis
• Stability and degradation testing
• Comparative GHRH analogue research

The receiving laboratory is responsible for determining and validating appropriate concentrations, controls and analytical procedures.

Analytical Research

Tesamorelin may be suitable for professional analytical applications involving:

• High-performance liquid chromatography
• Liquid chromatography–mass spectrometry
• Peptide identity confirmation
• Molecular-weight analysis
• Amino-acid-sequence verification
• Purity assessment
• Stability testing
• Degradation profiling
• Solubility assessment
• Reference-material comparison
• Formulation compatibility
• Analytical method development

Because Tesamorelin contains an N-terminal lipid modification, analytical methods should be validated specifically for this compound.

Product Specifications

Product characteristic	Information
Product name	Tesamorelin
Alternative designation	TH9507
Product category	Synthetic research peptide
Compound type	Stabilised GHRH analogue
Peptide length	44 amino acids
Structural basis	Complete human GRF 1–44 sequence
Molecular modification	N-terminal trans-3-hexenoyl group
Primary research target	GHRH receptor
Main research pathway	Growth hormone and IGF-1 axis
Approximate molecular weight	5.1 kDa
Form	Lyophilised research material
Presentation	Securely sealed research vial
Documentation	Batch-specific analytical information
Packaging	Secure and discreet packaging
Intended application	Scientific, analytical and laboratory research

Lyophilised Research Format

Tesamorelin is supplied as a lyophilised research material in a securely sealed vial. Lyophilisation removes moisture and helps support peptide stability during controlled storage and transportation. Minor differences in physical appearance may occur because of product quantity, production conditions and residual moisture. Physical appearance alone should not be used to establish product identity, purity or analytical quality. Researchers should review the documentation associated with the applicable batch before beginning laboratory work.

Quality and Product Transparency

Peptides Divas focuses on clearly displayed product specifications, professional handling and batch-level traceability. Available analytical information may include:

• Product identification
• Peptide sequence
• Batch or lot number
• Reported purity
• HPLC analysis
• Mass-spectrometry data
• Molecular-weight information
• Testing information
• Product appearance
• Storage recommendations

This provides researchers with clear and traceable information for the applicable product batch.

Storage Information

Store Tesamorelin in its original sealed packaging according to the conditions displayed on the product label and applicable batch documentation. Protect the research material from:

• Direct sunlight
• Excessive heat
• Moisture
• Contamination
• Damaged packaging
• Repeated temperature fluctuations
• Unnecessary exposure to air

The receiving laboratory is responsible for establishing appropriate preparation, handling and storage procedures for its specific research protocol.

Why Choose Tesamorelin?

Tesamorelin provides a clearly defined and stabilised full-length GHRH analogue for advanced receptor and endocrine research. Key research advantages include:

• Complete 44-amino-acid human GRF sequence
• Specialised N-terminal hexenoyl modification
• Relevant for GHRH receptor studies
• Suitable for pituitary signalling research
• Useful for GH–IGF-1 axis models
• Valuable for peptide-stability analysis
• Suitable for comparative GHRH research
• Convenient lyophilised presentation
• Clear batch-specific product information

Why Order from Peptides Divas?

Peptides Divas combines carefully selected research materials with fast, dependable and professional service. Customers benefit from:

• Clearly displayed product specifications
• Batch-specific analytical information
• Fast order processing
• Secure and discreet packaging
• Trackable shipping options
• Careful vial protection
• Responsive customer support
• Reliable European delivery

Choose Tesamorelin from Peptides Divas for advanced laboratory research involving GHRH receptor activity, pituitary signalling, the GH–IGF-1 axis and stabilised peptide design. For laboratory research use only. Not intended for human or veterinary use.